ArticleThe Canadian veterinary journal = La revue veterinaire canadienne2025
Antemortem diagnostic tests and treatment outcomes using ivermectin in 13 cases of presumptive feline neurocuterebriasis.
Article in The Canadian veterinary journal = La revue veterinaire canadienne, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Limited reports exist on the antemortem presumptive diagnosis and treatment of feline neurocuterebriasis. A 3-day treatment protocol reported for 3 cats had no adverse effects. This protocol comprised ivermectin (0.4 mg/kg), diphenhydramine (4 mg/kg), and dexamethasone (0.1 mg/kg) given q24h. Objective: To describe the treatment outcomes for cats that received the 3-day ivermectin protocol and antemortem diagnostic methods used before. Animals and procedure: Medical records from a single veterinary referral centre were searched to identify cats treated with the 3-day protocol. Variables extracted included signalment, season, history, neurological examination findings, and advanced diagnostic tests, as well as outcomes based on follow-up. Results: Thirteen cats were diagnosed based on advanced imaging. Ten of 13 also underwent cerebrospinal fluid analysis. Other diagnostic factors included season (July through September), signalment (young to middle-aged), lifestyle (outdoor access), history (7/13 cats showed upper respiratory signs preceding neurological deficits), and clinical signs (central neurological deficits). After being treated with the 3-day ivermectin protocol, 10/13 cats improved. Three cats were euthanized after showing worsening clinical signs. Conclusion and clinical relevance: Outcomes using the 3-day ivermectin protocol appeared favorable. This provided insight about a treatment option for a periodic cause of feline encephalomyelopathy that has potential for deployment in first-opinion practice.
Indexed as
Identifiers
39781413PMC11705184What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.